• NeuroSense Therapeutics Ltd is trading at $0.74, up 5.7% in pre-market sessions, potentially driven by recent insider buying.
  • On June 16, 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each acquired 250,000 ordinary shares at $0.80 per share in a private placement.
  • This insider acquisition, at a premium to the previous day's closing price of $0.70, suggests strong executive confidence in the company.
  • The company also recently received patent grants in Japan (June 9, 2026) and South Korea (June 11, 2026) for its lead drug candidate PrimeC for ALS.